Greg Anglin

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Infusion-related reactions in donanemab-treated participants with early symptomatic Alzheimer's disease.

Infusion-related reactions in donanemab-treated participants with early symptomatic Alzheimer's disease.

Journal: Alzheimer's & dementia (New York, N. Y.)

Published: December 10, 2025

Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease.

Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease.

Journal: Alzheimer's & dementia (New York, N. Y.)

Published: May 20, 2025

Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies.

Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies.

Journal: The Journal of clinical endocrinology and metabolism

Published: December 01, 2022

Clinical Trial Drug Safety Assessment for Studies and Submissions Impacted by COVID-19.

Clinical Trial Drug Safety Assessment for Studies and Submissions Impacted by COVID-19.

Journal: Statistics in biopharmaceutical research

Published: June 30, 2021

Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine.

Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine.

Journal: Cephalalgia : an international journal of headache

Published: April 29, 2020

What is clearance worth? Patients' stated risk tolerance for psoriasis treatments.

What is clearance worth? Patients' stated risk tolerance for psoriasis treatments.

Journal: The Journal of dermatological treatment

Published: May 13, 2017

Effective Partnering in Conducting Benefit-Risk Patient Preference Studies: Perspectives From a Patient Advocacy Organization, a Pharmaceutical Company, and Academic Stated-Preference Researchers.

Effective Partnering in Conducting Benefit-Risk Patient Preference Studies: Perspectives From a Patient Advocacy Organization, a Pharmaceutical Company, and Academic Stated-Preference Researchers.

Journal: Therapeutic innovation & regulatory science

Published: January 01, 2017

Implementation of Structured Benefit-Risk Assessments in Marketing Authorization Applications: Lessons Learned.

Implementation of Structured Benefit-Risk Assessments in Marketing Authorization Applications: Lessons Learned.

Journal: Therapeutic innovation & regulatory science

Published: November 01, 2016

Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.

Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.

Journal: Diabetes, obesity & metabolism

Published: June 09, 2016

Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.

Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.

Journal: Diabetes care

Published: May 05, 2016

Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.

Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.

Journal: Diabetes, obesity & metabolism

Published: November 30, 2015

Showing 1-11 of 11

Last Updated: 09/26/2026